Larry Wittenberg is a senior partner in Goodwin’s Technology Companies & Life Sciences group and Co-Chair of the firm’s Healthcare Technology and Services practice. Mr. Wittenberg co-founded the firm’s Life Sciences practice and previously served as Co-Chair of that practice and as national Co-Chair of Goodwin's Technology Companies & Life Sciences group. He has more than 30 years’ experience representing life science and healthcare technology companies, ranging in size from start-ups to public companies, in corporate and intellectual property transactions and general corporate matters. This work has included numerous venture capital financings, public offerings, mergers and acquisitions, strategic alliances, joint ventures, licenses and technology transfer agreements. Mr. Wittenberg also represents venture capital groups on their investments in life sciences companies and investment banks in connection with public and private financings. He has structured and negotiated corporate partnering transactions with numerous global pharmaceutical companies.





Mr. Wittenberg’s practice focuses primarily on biotechnology, medtech and healthcare IT companies. His recent representations include:

  • Acetylon Pharmaceuticals, Inc. in its collaborative agreement with Celgene Corporation providing for $100 million in non-dilutive development financing and a buyout option of up to $1.7 billion
  • athenahealth, Inc, a provider of cloud-based electronic health records, practice management and care coordination services to doctors and hospitals, in its $293 million acquisition of Epocrates, Inc., a developer and provider of one of the most widely-used clinical information tools for healthcare professionals
  • Action Pharma, in the $110 million sale of the rights to develop and commercialize the kidney drug compound AP214 to Abbott Laboratories
  • Abide Therapeutics, Inc., in its $430 million collaboration with Merck in the metabolic disease and diabetes fields
  • Abide Therapeutics in its collaborative agreement with Celgene Corporation
  • Akashi Therapeutics in its $100 million partnership with Gruenthal Group
  • Dragonfly Therapeutics in its $33 million collaborative agreement with Celgene Corporation 
  • Patient Ping in its $31 million Series B financing
  • QPID Health in its sale to eviCore healthcare
  • Vascular Biogenics in its $15 million follow-on public offering
  • C4 Therapeutics in its launch from Dana-Farber Cancer Institute, $73 million Series A financing
  • C4 Therapeutics in its strategic collaboration with Roche
  • C4 Therapeutics in its strategic collaboration with Calico Life Sciences
  • Vividion Therapeutics in its $50 million Series A financing
  • Acetylon Pharmaceuticals in its spin-out of Regenacy Pharmaceuticals and sale to Celgene Corporation
  • C4 Therapeutics in its strategic collaboration with Biogen
  • Dragonfly Therapeutics in its strategic collaboration with Merck
  • C4 Therapeutics in the extension and revision of its strategic collaboration with Roche
  • Skyhawk Therapeutics in its strategic collaboration with Biogen
Professional Activities

Mr. Wittenberg serves on the board of directors of MassBio, an association of more than 600 biotechnology companies, universities, academic institutions and others dedicated to advancing cutting edge research.

Professional Experience

Prior to joining Goodwin, Mr. Wittenberg was a partner in the Business Practice Group at Testa, Hurwitz & Thibeault, where he co-founded and headed its Life Sciences Practice and co-chaired its Business Practice Group.


Mr. Wittenberg has been selected for inclusion in U.S. News-Best Lawyers.

In The News









J.D., 1979
Harvard Law School

(cum laude)

B.A., 1976
Cornell University

(magna cum laude)



Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique